Zobrazeno 1 - 10
of 150
pro vyhledávání: ''
Autor:
Shaima’a Hamarsheh, Justus Duyster, Lukas Braun, Franziska M. Uhl, Sandra Duquesne, Geoffroy Andrieux, Robert Zeiser, Melanie Boerries, Annette Schmitt-Graeff, Lena Osswald, Christine Dierks, Tilman Brummer, Claudius Klein
Publikováno v:
Molecular Cancer Research. 19:1596-1608
The bone marrow microenvironment (BMME) is key player in regulation and maintenance of hematopoiesis. Oncogenic RAS mutations, causing constitutive activation of multiple tumor-promoting pathways, are frequently found in human cancer. So far in hemat
Publikováno v:
Molecular Cancer Research. 18:835-846
Through the use of an unbiased, genome-scale CRISPR modifier screen, we identified NF1 suppression as a mechanism of resistance to EGFR inhibition in NRAS/KRAS/BRAFV600-wild-type colorectal cancer cells. Reduced NF1 expression permitted sustained sig
Autor:
Carmen Maria Barnes, Ellen Filvaroff, Shi Tao, Mehnaz Malek, Gordon L. Bray, Winfried Elis, Yumin Dai, Konstantinos Mavrommatis, Lixin Qiao, Terri Jones, Ida Aronchik, Beebe Lisa, Matt Labenski
Publikováno v:
Molecular Cancer Research. 17:642-654
As a critical signaling node, ERK1/2 are attractive drug targets, particularly in tumors driven by activation of the MAPK pathway. Utility of targeting the MAPK pathway has been demonstrated by clinical responses to inhibitors of MEK1/2 or RAF kinase
Autor:
Akshata Udyavar, Junko Aimi, Ching-Wei Chang, Mark R. Lackner, Timothy R. Wilson, Heidi Savage, Jill M. Spoerke, Richard Bourgon, Anneleen Daemen, Joyce O'Shaughnessy
Publikováno v:
Molecular Cancer Research. 17:97-108
The identification of early breast cancer patients who may benefit from adjuvant chemotherapy has evolved to include assessment of clinicopathologic features such as tumor size and nodal status, as well as several gene-expression profiles for ER-posi
Autor:
Raghu Kalluri, Valerie S. LeBleu, Yingqi Teng, Hans Petter Eikesdal, Julienne L. Carstens, Hikaru Sugimoto, Lisa M. Becker, Keizo Kanasaki, Akane Kizu
Publikováno v:
Molecular Cancer Research. 16:1568-1578
Deregulated transforming growth factor-β (TGFβ) signaling is a common feature of many epithelial cancers. Deletion of TGFβ receptor type 2 (TGFBR2) in fibroblast specific protein-1 (FSP1)-positive stromal cells induces squamous cell carcinoma in t
Autor:
Isaac K. Nardi, Dan J. Raz, Lu Yang, Jinhui Wang, Jami Wang, Rajendra P. Pangeni, Xinwei Yun, Melissa Bonner, Ming Gao, Keqiang Zhang, Jun Wu
Publikováno v:
Molecular Cancer Research. 16:1161-1171
Loss of monoubiquitination of histone H2B (H2Bub1) was found to be associated with poor-differentiation and enhanced malignancy of lung adenocarcinoma. This study investigated the association and impact of the ubiquitin-specific peptidase 22 (USP22),
Autor:
Byung-Gyu Kim, Hye Jin Ham, Jung-Guk Kim, Ji-Hyun Kim, Soo-Young Park, Keun-Gyu Park, Jung Yi Lee, Yeon-Kyung Choi, Se Young Jang, Mi Jin Kim, Hui-Jeon Jeon, Inkyu Lee
Publikováno v:
Molecular Cancer Research. 15:1230-1242
The tyrosine kinase inhibitor sorafenib is the only therapeutic agent approved for the treatment of advanced hepatocellular carcinoma (HCC), but acquired resistance to sorafenib is high. Here, we report metabolic reprogramming in sorafenib-resistant
Autor:
Rafael Renatino Canevarolo, Constantine N. Logothetis, Christopher L. Cubitt, Mark B. Meads, Amit A. Kulkarni, Maria D Coelho Siqueira Silva, Yosef Landesman, Oliver A. Hampton, Christopher J. Walker, Praneeth Reddy Sudalagunta, Raghunandan Reddy Alugubelli, Gabriel DeAvila, Qi Zhang, Kenneth H. Shain, Ariosto S. Silva
Publikováno v:
Cancer Research. 81:1061-1061
Introduction. Multiple myeloma (MM) is an all but incurable plasma cell malignancy without predictive biomarkers for approved therapies. Selinexor (SELI), a nuclear export inhibitor targeting exportin 1 (XPO1), is approved with dexamethasone (DEX) wi
Autor:
Han Zhang, Dayong Zhai, Herve Aloysius, Evan Rogers, Xin Zhang, Ana Parra, Vivian Nguyen, Ung Jane, Dong Lee, Wei Deng, Maria Barrera, Jessica Cowell, Brion W. Murray
Publikováno v:
Cancer Research. 81:1469-1469
Three generations of ALK inhibitors are approved for the treatment of ALK+ NSCLC but their efficacy is often limited by ALK resistance mutations. The solvent front mutation G1202R and gatekeeper mutation L1196M are major resistance mechanisms to the
Publikováno v:
Clinical Cancer Research. 23:3884-3895
Purpose: Human papillomavirus 16 (HPV-16) is an important risk factor in head and neck cancer (HNC). Studies suggest that miRNAs play an important role in cancer; however, their role in HPV-mediated oncogenesis remains largely unknown. We investigate